In agreement with previous studies that the pre-treatment of mice with LPS renders the animals more susceptible to the development of signs and symptoms of HUS following intraperitoneal (i.p.)administration of Stx28,31,40, our results also showed an increased number and Stx2-binding capability of Stx2+ leukocytes harvested from LPS-primed mice (Fig. 6E, Table 1). The gene discussed is STX2; the disease is hemolytic-uremic syndrome.